Source: EPI Health
The EP Group (privately held parent company of EPI Health, Inc.) today announced the acquisition of EPI Health, LLC (“EPI Health”) by Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN). Novan will host a conference call and webcast, today, March 11, 2022, at 8:30 a.m. ET (details below).
EPI Health is an established specialty dermatology company that markets innovative prescription therapies to dermatologists to improve patients’ quality of life. It is one of the leading companies in the US dermatology sector. EPI Health has an established sales force and commercial team with existing, deep market relationships across the dermatology community.
“EPI Health has established itself as a leading commercial dermatology company and I am excited about the synergies this transaction offers both Companies. As of today, we are now a fully integrated specialty dermatology company with a robust pipeline of development candidates and have the commercial infrastructure to realize the full value each program brings,” commented Paula Brown Stafford, Chairman and Chief Executive Officer of Novan. “I am pleased to welcome EPI Health to the Novan family.”
Novan is a specialty dermatology pharmaceutical company focused on developing therapeutic products for skin diseases. The Company is leveraging its core platform of nitric oxide-based science and clinical translation expertise to bring new medicines to market. Novan announced positive results in a Phase 3 study from its lead candidate berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum and is advancing to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) targeted in Q4 2022.
Following the acquisition, the Company will employ approximately 100 staff with over 300 years of combined excellence in dermatology product development, commercialization, and sales.
“The combined entity has the opportunity to be a force multiplier for both companies, creating a pharmaceutical engine that has the capabilities to discover innovative therapies, develop them through the clinic and through a proven commercial platform bring medications to patients with unmet needs,” added John Donofrio, President of EPI Health and now Chief Operating Officer of Novan.